ScreenPoint Medical Launches Transpara™ DBT — an AI-based Decision-Support Engine for Digital Breast Tomosynthesis

Share Article

Utilizing breakthrough image analysis and deep learning technologies, the Transpara DBT application provides information to significantly improve reading workflow for DBT on breast reading workstations.

“By providing interactive decision support to radiologists, we aim to help all readers achieve better performance and improve their workflow, representing a significant innovation in breast cancer screening.

ScreenPoint Medical announced the launch of Transpara™ DBT, an AI-driven decision support software engine, designed to assist radiologists with the reading of digital breast tomosynthesis (DBT) and mammography exams on breast reading workstations, here, at the European Congress of Radiology (ECR), Vienna, Austria, February 28 – March 4, 2018. (Hall X1 - # 108).

Utilizing breakthrough image analysis and deep learning technologies, the Transpara DBT application provides information to significantly improve reading workflow for DBT on breast reading workstations. With Transpara, the reader can automatically jump to a relevant DBT slice in both the CC and MLO 3D data, by simply clicking on a suspicious region in a synthetic mammogram. Transpara DBT marks the lesion in the relevant slices and provides quantitative decision support for individual soft tissue lesions and calcifications. Interactive decision support is a proven method to boost reading performance for soft tissue lesions and Transpara improves radiologists’ reading accuracy and confidence in their assessment.

In addition, Transpara DBT combines analysis of soft tissue lesions and calcifications, if present, from all available views of an exam to compute a single score for the case on a scale of 1 to 10. This represents categories with increasing occurrence of cancer. Healthcare professionals and organizations can use this Transpara Score to automatically identify exams that are highly likely to be normal and to help identify cases that need increased attention.

“Transpara DBT was developed with the goal of improving the efficiency of reading tomosynthesis exams. By providing interactive decision support to radiologists, we aim to help all readers achieve better performance and improve their workflow, representing a significant innovation in breast cancer screening,” said Prof. Nico Karssemeijer, PhD, CEO of ScreenPoint Medical.

The Transpara DBT software engine is multi-vendor and communicates via DICOM, allowing integration into PACS and mammography reading workstations. The Transpara algorithms use the full 3D information in DBT data and have been trained on very large databases including thousands of examples of breast cancer and false positives. Transpara DBT is an extension of the mammography product, which has European regulatory approval (CE Mark) for use with Hologic, GE, Philips and Siemens, and is installed at leading centers throughout Europe.

About ScreenPoint Medical BV
ScreenPoint Medical develops and markets image analysis technology and services for automated reading of mammograms and digital breast tomosynthesis exams, exploiting Big Data, Deep Learning and the latest developments in Artificial Intelligence. ScreenPoint Medical was founded in 2014 by Nico Karssemeijer and Michael Brady, two experts in breast imaging, machine learning, computer vision, and computer-aided detection. The main office is in Nijmegen, The Netherlands.

Media Contact:
Chris K. Joseph
+1 510/435-4031
chris(at)ckjcomm(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Land
ScreenPoint Medical
+31 686858837
Email >
Visit website